Literature DB >> 2112994

Selegiline and Parkinson's disease. Protective and symptomatic considerations.

L I Golbe1, J W Langston, I Shoulson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112994     DOI: 10.2165/00003495-199039050-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  38 in total

1.  (-)Deprenyl in the treatment of Parkinson's disease.

Authors:  W Birkmayer; P Riederer; M B Youdim
Journal:  Clin Neuropharmacol       Date:  1982       Impact factor: 1.592

2.  Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy.

Authors:  D H Lee; M Mendoza; M T Dvorozniak; E Chung; M H van Woert; M D Yahr
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1989

3.  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group.

Authors: 
Journal:  Arch Neurol       Date:  1989-10

4.  Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline).

Authors:  M D Yahr; M R Mendoza; D Moros; K J Bergmann
Journal:  Acta Neurol Scand Suppl       Date:  1983

5.  Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.

Authors:  J Presthus; A Hajba
Journal:  Acta Neurol Scand Suppl       Date:  1983

6.  Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients.

Authors:  T S Elizan; M D Yahr; D A Moros; M R Mendoza; S Pang; C A Bodian
Journal:  Arch Neurol       Date:  1989-12

7.  Recent observations on the clinical pharmacology of (-)deprenyl.

Authors:  G M Stern; A J Lees; M Sandler
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

8.  Overview of present day treatment of Parkinson's disease.

Authors:  M D Yahr
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

9.  Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B.

Authors:  A Kalir; A Sabbagh; M B Youdim
Journal:  Br J Pharmacol       Date:  1981-05       Impact factor: 8.739

10.  Experience with selegiline in the treatment of Parkinson's disease.

Authors:  W Poewe; F Gerstenbrand; G Ransmayr
Journal:  J Neural Transm Suppl       Date:  1987
View more
  5 in total

Review 1.  New directions in the drug treatment of Parkinson's disease.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 2.  Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Authors:  H M Bryson; R J Milne; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

Review 3.  Time to change the blind men and the elephant approach to Parkinson disease?

Authors:  Brad A Racette; Allison W Willis
Journal:  Neurology       Date:  2015-06-12       Impact factor: 9.910

Review 4.  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.

Authors:  P Chrisp; G J Mammen; E M Sorkin
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 5.  Diagnostic and pharmacological approaches in Alzheimer's disease.

Authors:  C Hermann; R G Stern; M F Losonzcy; S Jaff; M Davidson
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.